financetom
Business
financetom
/
Business
/
Chinese automaker Geely steps up challenge to BYD with new hybrid tech
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Chinese automaker Geely steps up challenge to BYD with new hybrid tech
Nov 3, 2024 2:44 PM

BEIJING, Oct 30 (Reuters) - China's Geely Automobile

Holdings ( GELYF ) took the wraps off its latest hybrid technology on

Wednesday, boasting some better fuel economy and driving range

figures than rival technology from local plug-in hybrid champion

BYD .

The Leishen EM-i technology can consume just 2.62 litres of

fuel per 100 kilometres (62.1 miles) and offer a combined range

- using both gasoline and battery - of 2,390.5 km, Geely said,

citing media test results.

BYD's latest-generation plug-in hybrid system, launched in

May, touts fuel consumption of 2.9 litres per 100 km on depleted

batteries and a driving range of 2,100 km with a fully charged

battery and a full gasoline tank.

The first car running on Geely's new hybrid system, the

Galaxy Starship 7 crossover, can achieve fuel consumption of

three litres per 100 km in tests on real roads, Geely said.

Geely's Leishen hybrid technologies will also be used in

Renault, Volvo and Lotus-branded cars, it added.

The race for improved hybrid fuel technology comes as Geely

seeks to close the gap with BYD amid intensifying competition in

the world's largest auto market, as China's weak economy weighs

on electric vehicle sales growth.

BYD sat atop China's EV and plug-in hybrid sales rankings

with a 34.6% share of the market in the first nine months of

this year, well ahead of second-placed Geely with 7.4%, industry

data showed. Tesla took the third spot with 6.5%.

BYD smashed its quarterly sales record in July-September,

primarily driven by strong growth in plug-in hybrid sales, which

jumped 76% to 685,830 vehicles, according to Reuters'

calculations based on BYD's monthly data.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BRIEF-CCH Holdings Files For U.S IPO With SEC - SEC Filing
BRIEF-CCH Holdings Files For U.S IPO With SEC - SEC Filing
Aug 27, 2025
Aug 27 (Reuters) - CCH Holdings Ltd: * CCH HOLDINGS LTD - FILES FOR US IPO WITH SEC - SEC FILING * CCH HOLDINGS LTD - TO APPLY FOR NASDAQ LISTING UNDER SYMBOL 'CCHH' - SEC FILING * CCH HOLDINGS LTD: CATHAY SECURITIES INC IS UNDERWRITER TO IPO ;)) ...
Rheinmetall wants to take over German shipbuilder NVL, Bild reports
Rheinmetall wants to take over German shipbuilder NVL, Bild reports
Aug 27, 2025
BERLIN, Aug 27 (Reuters) - Defence group Rheinmetall wants to take over German shipbuilder Naval Vessels Luerssen, the German daily Bild reported on Wednesday, citing industry sources. According to Bild, the Luerssen family, who own the shipbuilder, plan to divest its military shipyards in Hamburg, Wilhelmshaven and Wolgast to focus on building megayachts. Rheinmetall's supervisory board intends to consider the...
Abercrombie & Fitch Lifts Full-Year Guidance as Second-Quarter Results Top Views
Abercrombie & Fitch Lifts Full-Year Guidance as Second-Quarter Results Top Views
Aug 27, 2025
01:20 PM EDT, 08/27/2025 (MT Newswires) -- Abercrombie & Fitch ( ANF ) upgraded its fiscal 2025 outlook on Wednesday after the apparel retailer's second-quarter results exceeded Wall Street's estimates, though earnings fell year over year. The company now expects full-year earnings between $10 and $10.50 per share, lifting the middle point versus its prior outlook of $9.50 to $10.50....
Vor Bio's Investigational Drug Scores Phase 3 Win In Autoimmune Kidney Disease Trial
Vor Bio's Investigational Drug Scores Phase 3 Win In Autoimmune Kidney Disease Trial
Aug 27, 2025
On Wednesday, Vor Bio Inc. announced that its collaborator, RemeGen Co., Ltd., achieved the primary endpoint in Stage A of a Phase 3 clinical study in China evaluating telitacicept in adults with IgA nephropathy (IgAN). IgA nephropathy, also known as Berger’s disease, is an autoimmune kidney disease where abnormal clumps of the antibody immunoglobulin A (IgA) deposit in the kidneys’...
Copyright 2023-2026 - www.financetom.com All Rights Reserved